Month: April 2021
Repurposing (repositioning, re-profiling, or re-tasking) a drug potentially saves years of costly testing from going to waste and potentially providing a higher chance of success. “Perhaps most importantly, the risk of failure is lower […] because the repurposed drug has already been found to be sufficiently safe in preclinical models and humans if early-stage trials have been completed...
Improve the Value of Your Molecule's Testing with Expert Insight
Our expert team of DDI and drug metabolism consultants can help you piece together the data for a successful data package that meets regulatory expectations for thorough risk assessment of a new or repurposed compound
Read our Follow-Up Interview in Outsourcing Pharma
Find the Q&A between Director of Scientific Consulting, Dr. Maciej Czerwinski, and the editorial team at Outsourcing Pharma for more answers about how DDI testing and data interpretation adds value to the drug repurposing process